Cephalalgia
Share

Cephalalgia

2015 Impact Factor: 6.052
2015 Ranking: 24/256 in Neurosciences | 13/192 in Clinical Neurology
2016 Release of Journal Citation Reports, Source: 2015 Web of Science Data
Published in Association with International Headache Society

Editor-in-Chief
Arne May Neurologische Universitaetsklinik, Germany


eISSN: 14682982| ISSN: 03331024|Current volume: 36|Current issue: 9 Frequency: 14 Times/YearTimes/Year

To submit your manuscript online, please click here: SAGE TRACK

Cephalalgia contains original papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications.

Published monthly on behalf of the International Headache Society, Cephalalgia's rapid review averages 5 ½ weeks from author submission to first decision. Readers receive timely cutting edge original articles, editorials, reviews, letters and clinical correspondence on both clinical and basic research. Subscribers also receive themed Supplements and news on events within the headache community.

Recently published topics include:

· diagnosis and management of primary and secondary headaches and related syndromes

· pathophysiology

· mechanisms

· pharmacology

· epidemiology

· imaging

· genetics

· medico-legal aspects

· pharmacoeconomics.

This journal is a member of the Committee on Publication Ethics (COPE).

Previous Editors of the Journal:
Ottar Sjaastad (Founding Editor), Marcia Wilkinson, K Michael Welch, Peter J Goadsby.

Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications.

Published monthly on behalf of the International Headache Society, Cephalalgia's rapid review averages
5 ½ weeks from author submission to first decision. Readers receive timely cutting edge original articles, editorials, reviews, letters and clinical correspondence on both clinical and basic research. Subscribers also receive themed Supplements and news on events within the headache community. Recently published topics include:

  • diagnosis and management of primary and secondary headaches and related syndromes
  • pathophysiology
  • mechanisms
  • pharmacology
  • epidemiology
  • imaging
  • genetics
  • medico-legal aspects
  • pharmacoeconomics.

This journal is a member of the Committee on Publication Ethics (COPE).

Associate Editors
Frank Andrasik University of Memphis, USA
Massoud Ashina Glostrup Hospital, University of Copenhagen, Denmark
Rafael Benoliel Rutgers University, USA
Rami Burstein Beth Israel Deaconess Medical Center, USA
Andrew Charles University of California Los Angeles, USA
Hans-Christoph Diener University Essen, Germany
Anne Ducros Montpellier University Hospital, Montpellier, France
Lars Edvinsson University Hospital of Lund, Sweden
Stefan Evers University of Münster, Germany
Michel D. Ferrari Leiden University Medical Centre, The Netherlands
Edith Hamel Montreal Neurological Institute, Canada
Andrew Hershey University of Cincinnati, USA
Philip R. Holland King's College London, UK
Elizabeth Loder Spaudling Rehabilitation Hospital, USA
Delphine Magis CHR Citadelle, Belgium
Karl Messlinger University of Erlangen Nurenberg, Germany
Frank Porreca University of Arizona College of Medicine, USA
Michael B. Russell Akershus University, Norway
Ann Scher Uniformed Services University, USA
Todd Schwedt Mayo Clinic - Neurology, USA
Shuu-Jiun Wang Taipei Veterans General Hospital, Taiwan
Managing Editor
Biostatics Editor
Richard P. Chiacchierini R. P. Chiacchierini & Associates LLC, USA
Jayawant Mandrekar Mayo Clinic, USA
Book Review Editor
Richard Peatfield Princess Margaret Migraine Clinic, UK
Historical Section Editor
Peter J. Koehler Atrium Medical Center, The Netherlands
Junior Editor
Larus S. Gudmundsson University of Iceland, Iceland
Andrea Harriott Mayo Clinic Florida, United States
Jan Hoffmann University Medical Centre Hamburg, Germany
Publishing & Scientific Integrity Advisor
Peter J. Goadsby King's College London, UK
Ombudsman
David W. Dodick Mayo Clinic College of Medicine, USA
  • BIOSIS database
  • Cab Abstracts
  • Chemical Abstracts Service (CAS)
  • Current Contents / Clinical Medicine
  • Current Contents / Life Sciences
  • EMBASE/Excerpta Medica
  • INIS Atomindex
  • INIS Database (0nline and CD Rom)
  • PsycINFO
  • Science Citation Index
  • Science Citation Index Expanded
  • Thomson Reuters: BIOSIS Previews
    1. Peer review policy
      1.1 Fast track review
    2. Article types
      2.1 Research article preparation guidelines
    3. How to submit your manuscript
    4. Publishing policies
      4.1 Plagiarism policy
      4.2 Journal contributor’s publishing agreement   
      4.3 SAGE Choice
    5. Declaration of conflicting interests policy
    6. Other conventions
    7. Acknowledgments
      7.1 Funding acknowledgement
    8. Permissions
    9. Manuscript style
      9.1 File types
      9.2 Journal style
      9.3 Reference style
      9.4 Manuscript preparation
      9.4.1 Title Page
      9.4.2 Keywords and abstracts: Helping readers find your article online
      9.4.3 Structuring your abstract
      9.4.4 Corresponding author contact details
      9.4.5 Clinical relevance summaries
      9.4.6 Guidelines for submitting artwork, figures and other graphics
      9.4.7 Guidelines for submitting supplemental files
      9.4.8 English language editing services
    10. After acceptance
      10.1 Proofs
      10.2 E-Prints and complimentary copies
      10.3 SAGE production
      10.4 OnlineFirst publication
    11. Further information

    Cephalalgia is a medical-neurological journal in the field of headache research, and is the official journal of the International Headache Society.

     

    1. Peer review policy

    Cephalalgia operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author.

    Generally each manuscript is reviewed by at least two referees. All manuscripts are reviewed as rapidly as possible, and an editorial decision is generally reached within 5-6 weeks of submission.

    Obligate external peer-review is not mandatory. After review by the Editor-in-Chief and Associate Editor, a decision is made whether to send the manuscript for external peer review.

    In addition case reports may be also be reviewed by the Editor-in-Chief and Associate Editor without external peer review or with only 1 external peer reviewer.

    Please note that in any papers where the Editor-in-chief is an author the processing of the manuscript is handled by an Associate Editor and the Editor-in-chief is totally blinded from the procedure and will never have access to the peer reviewer details.

    1.1 Fast-track review

    Cephalalgia provides a fast-track review option whereby two Associate Editors may review a manuscript within 72 hours and on-line publication occurs within 4 weeks of acceptance. The cost of such rapid review is $900.00 USD and this payment is to cover the time of the Associate Editors. Please note that this payment is strictly to facilitate the rapid review process and does not in any way guarantee acceptance or publication of your article.

    If you wish to make use of this facility please choose the ‘fast track review’ option in the article type dropdown menu when submitting your article. Please note if you choose the ‘fast-track’ review option you are agreeing to pay the $900.00 USD for this service.

    Back to top

     

    2. Article types

    Cephalalgia publishes original papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. The Journal considers the following kinds of article for publication:

    1. Editorials
    2. Viewpoints/perspectives
    3. Review Articles
    4. Original research papers
    5. Brief reports
    6. Clinical correspondence
    7. Letters
    8. Imaging in Headache Medicine

    Original research papers
    If you are submitting a basic science research article you are required to include two to five bullet points clearly summarizing the article highlights of your research. This summary will appear at the end of your article in a highlighted box entitled ‘article highlights’.
    If you are submitting a clinical based article you are required to include between two and five bullet points summarizing the clinical relevance of your research. This summary will appear at the end of your article in a highlighted box entitled ‘clinical implications’.

    The below table gives typical word counts for submissions to Cephalalgia, however these are not set, fixed limits and the Editors can be flexible where necessary. Nevertheless, please do try to make your articles concise and make every effort to reduce the word count.  Occasionally it may be necessary to go over the suggested word counts to accommodate important information but please note that Editors may still request that overly lengthy articles are reduced by the Authors.

    Table 1. Overview of recommended maximums for manuscript submissions to Cephalalgia

    Article Type

    Abstract

    Main Text Word* limit

    References**

    Figures

    Tables

    Viewpoints/
    perspectives

    N/A

    500

    3

    1

    1

    Review Articles
    Narrative review
    Systematic review

     

    200
    200

     

    4,000
    4,000

     

    100
    100

    As necessary for the requirements of the article

     

    As necessary for the requirements of the article

    Original Research Papers

    200

    3,000-3,500

    35

    As necessary for the requirements of the article

    As necessary for the requirements of the article

    Brief Reports / Clinical Correspondence

    150

    1,250 -1,500

    12

    2

    1

    Letter to the Editor

    N/A

    500

    3

    1

    1

    Imaging in Headache Medicine

    N/A

    100

    3

    2

    2

    * Excluding abstract and references.
    ** See section 9.3 for referencing styles

    2.1 Research article preparation guidelines

    General Aspects:

    Title: Use titles that describe the main aspect of your study, stimulate interest, are easy to read and concise, and state the design of the study (i.e., randomized controlled trial, case-control study, cohort study etc.). Main findings or interpretation of the study should not be included in the title.

    Abbreviations: Do not use abbreviations unless absolutely necessary. Often abbreviations make it difficult for readers to follow a paper, particularly if they are not experts in your field; consider abbreviating long names of chemical substances, genetic polymorphisms and terms for therapeutic combinations. It is appropriate to use abbreviations that are largely known, such as DNA. If abbreviations are used in tables or figures to save space, please explain all abbreviations in the footnote or legend. 

    Introduction: Briefly introduce the background and significance to concisely set up the context of the specific research question for readers. Remember that your audience and the readership are generally knowledgeable about the issues related to common headache disorders and these aspects do not need to be repeated. Economy of words is important and comments should be essential and specific to the subject matter of the manuscript and need for the study. End the introduction with a clear statement of the study’s objectives or hypotheses.

    Methods: For studies involving humans, describe how participants were selected and enrolled, and the sites or setting from which they were recruited. Describe study procedures including any details of interventions (if applicable), measurement and classification of main exposure (if applicable) and outcomes, and other data collection techniques. Consider the use of a figure to show study processes. Report how many individuals were eligible, how many declined to participate and how many were lost to follow-up. For studies that have numerical data and use statistical inference, include a section that describe all details of the statistical analyses (how groups were compared, model building strategies, specific software(s) used, etc.). See also specific statistical reporting guidelines below.

    Results: Fully describe the sample and setting of the study (if applicable) and provide characteristics of your study population. Present the finding of the primary outcome first followed by the result of secondary outcomes, exploratory outcomes, and subgroup analyses. Consider presenting main results in tables or figures and avoid repeating the same numbers in text, tables, and figures.

    Discussion: We encourage authors to structure the discussion and cover the following aspects: Summary of the main findings (primary outcomes first followed by secondary outcomes), discussion on how the findings compare with previously published studies, a brief description on potential biological mechanisms (if applicable), clinical, scientific and/or public health implications, strengths and limitations, unanswered questions and suggestions for further targeted research (if applicable).

    Funding: For all studies, include a statement describing all and any funding sources and the role of each funding source for the study. If the study had no external funding source or if the funding source had no role in the study, state so explicitly.

    Ethics or Institutional Review Board Approval: Please clearly indicate that the study obtained appropriate approval (or a statement and explanation of why it was not required), including the name of the ethics committee(s) or institutional review board(s), the number/ID of the approval(s). For human studies, please also add a statement that participants gave informed consent before taking part.

    Study Protocol: If your study protocol is registered (ClinicalTrial.gov, etc.), please provide the registration number (required for intervention studies). We encourage the registration of observational study protocols.

     

    Specific reporting aspects:

    CONSORT
    Reports of clinical trials should adhere to the tenets of the CONSORT statement (JAMA 2001; 285: 1987-1991) . A flow chart MUST be provided describing the progress of patients through the trial. A checklist of CONSORT requirements MUST be completed and uploaded into the manuscript files system.  Alternatively, the forms may be sent to the Editorial Office by post, fax or scanned copies of the hand-signed forms can be e-mailed.

    PRISMA
    Systematic reviews and meta-analyses should adhere to the principles of the PRISMA statement (BMJ 2009; 339:b2535). The PRISMA flow diagram MUST be provided and the checklist MUST also be completed. Both forms MUST be completed and uploaded into the manuscript files system.  Alternatively, the forms may be sent to the Editorial Office by post, fax or scanned copies of the hand-signed forms can be e-mailed.

    SQUIRE
    These SQUIRE guidelines provide a framework for reporting formal, planned studies designed to assess the nature and effectiveness of interventions to improve the quality and safety of care. The checklists and guidelines are available here. Please include a completed SQUIRE checklist at manuscript submission.

    STROBE
    The STROBE Statement is referred to in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by the International Committee of Medical Journal Editors. The STOBE checklist MUST be completed and uploaded into the manuscript files system.  Alternatively, the forms may be sent to the Editorial Office by post, fax or scanned copies of the hand-signed forms can be e-mailed.

    Reporting checklists: Completed applicable checklists and appropriate documentation (flow diagram etc.) should be uploaded with your submission.

    ARRIVE (Animal Research: Reporting In Vivo Experiments)

    CARE (for preparing reporting case reports that to provide more complete and transparent reporting for brief reports manuscripts. Consider the CARE manuscript template available on their site)

    CONSORT Statement (for reporting of randomized controlled trials: please use the appropriate extension to the CONSORT statement, including the extension for writing abstracts)

    MOOSE (for reporting of meta-analyses of observational studies). Cephalalgia requires a copy of this completed checklist for meta-analyses of observational studies.  Upload the document along with your manuscript submission.  Download the MOOSE checklist.

    PRISMA (for reporting of systematic reviews and meta-analysis of randomized controlled trials). Please also see Section 6

    SQUIRE (for reporting improvements in quality and safety of care)

    STARD (for reporting of diagnostic accuracy studies)

    STREGA (for reporting of gene-disease association studies) STrengthening the REporting of Genetic Association studies – an extension of the STROBE statement

    STROBE (for reporting of observational studies in epidemiology) Checklist for cohort, case-control, and cross-sectional studies. Please also see Section 6

    Methodological/Statistical Guidelines

    Percentages: Report percentages to maximal of one decimal place (i.e., XX.X%). In studies with <300 participants it is recommended to show full numbers (i.e., XX%).

    P values: In the Methods section, please indicate whether you have calculated two- or one-tailed P values and which cut-off you have set for statistical significance. Please report all P values. Showing “n.s.” for not significant is not acceptable. For P values between 0.001 and 0.10, please report the value with three decimal places. For P values greater than 0.10, please report P values with two decimal places. For P values less than 0.001, report as “P<0.001.” Exceptions are genome-wide association studies. Do not only show P values for group differences but show the appropriate effect measure (i.e., relative risk, absolute risk, difference of means etc.).

    Relative risk estimates:  Show all relative risk estimates with appropriate (i.e., 95%) confidence intervals. Do not show more than two decimal places. In smaller studies, there is often only power to show one decimal place.

    The term relative risk is often used as a generic term for odds ratios, hazard ratios, or rate ratios. We encourage using the precise term depending on the model used to calculate the relative risk measure (i.e., odds ratio for logistic regression models, hazard ratio for Cox proportional hazard models). If you use the term “relative risk” as a generic term, please indicate in the Methods section what relative risk stands for (i.e., we used a logistic regression model to calculate odds ratios as a measure of the relative risk).

    Absolute event rate: Please indicate in the Table(s) or text how many people had the outcome event(s) of interest according to the exposure or intervention status. In other words, do not show just the relative risk estimate or proportions without showing how many people went into the calculation.

    Absolute risks: Please consider showing absolute risk (i.e., risk difference, attributable risk, etc.) in addition to showing relative risk estimates. Often relative risk are large when there is only a small absolute effect (i.e., in setting were either the exposure or the outcome are rare), which can lead to over interpretation of findings. On the other hand, please keep in mind that absolute effects assume causality in a specific setting when interpreting absolute effect estimates. So caution should be used before making strong inference, in particular from observational research (i.e., XX% of the outcome events are explained by the exposure or XX% of the outcome can be avoided when the exposure is eliminated).

    Trend: use the word trend only when you have tested a trend across a specific variable (i.e., dose response) and report an appropriate P value for trend.

    Model building:  We discourage the use of “stepwise” or automated selection procedure methods (i.e., such as forward or backward selection procedures) to build multivariable models. Exceptions are studies aiming to build prediction or prognostic models or studies that are set up to generate hypotheses for subsequent research (i.e., hypothesis generating studies, data mining, etc.). Regardless of the approach, the authors should clearly state in the Methods section how a multivariable model was built.

    Subgroup analyses: It is encouraged to limit the number of subgroup (or stratified) analyses. Subgroup analyses should be pre-specified and based on biological or clinical plausibility. P values of appropriate test for interaction should be provided. The inclusion of any not pre-specified subgroup or stratified analyses must be accompanied by a correction for multiple comparisons (e.g. Bonferroni).

    Missing data: Please report the amount of missing data and how you dealt with this.

    Back to top

     

    3. How to submit your manuscript

    Before submitting your manuscript, please ensure you carefully read and adhere to all the guidelines and instructions to authors provided below. Manuscripts not conforming to these guidelines may be returned to your Author Center. Specifically, please upload the elements of the manuscripts as single file(s) and in the correct format, main body (.doc or .rtf), tables (.doc, .xls, .tif), figures (.doc or image format such as .eps, .tif .jpeg are best), supporting documents (use the aforementioned formants, including .PDF).

    Please include Clinical Implications or Article Highlights in the main body of the manuscript prior to the reference list. The Clinical Implications or Article Highlights are also a required data entry field for the database.

    To ensure an expedient review of all manuscripts, and to assist the Editor and Associate Editors in allocating the most appropriate and knowledgeable reviewers for your article, please list five key references from your reference list, along with the senior author’s email address and contact information from each of these five references. The key references are reported in the database only, please do not include the key references within the main body of the manuscripts.

    Cephalalgia is hosted on SAGE track, a web based online submission and peer review system powered by ScholarOne© Manuscripts. Please read the Manuscript Submission guidelines below, and then simply visit http://mc.manuscriptcentral.com/cephalalgia to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. Please ensure the author account data is accurate before proceeding to the manuscript submission. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    Online Submission

    Submissions should be made by logging in and selecting the Author Centre and the ‘Click here to Submit a New Manuscript’ option. Follow the instructions on each page, clicking the ‘Next’ button on each screen to save your work and advance to the next screen. If at any stage you have any questions or require the user guide, please use the ‘Get Help Now’ button at the top right of every screen. Further help is available through ScholarOne’s® Manuscript CentralTM customer support at +1 434 817 2040 x 167.

    To upload your files, click on the ‘Browse’ button and locate the file on your computer. Select the designation of each file (i.e. main document, submission form, figure) in the drop down box next to the browse button. When you have selected all files you wish to upload, click the ‘Upload Files’ button. Review your submission (in both PDF and HTML formats) and then click the Submit button.

    You may suspend a submission at any point before clicking the Submit button and save it to submit later. After submission, you will receive a confirmation e-mail. You can also log back into your author centre at any time to check the status of your manuscript.

    Please ensure that you submit editable source files only. The main text should be in Microsoft Word or RTF, the tables as separate Word files, and the figures as separate EPS, JPEG or TIF files. Please ensure that your document does not include line numbers; the Cephalalgia SAGE track system will generate them for you, and then automatically convert your manuscript to PDF for peer review. All correspondence, including notification of the Editor’s decision and requests for revisions, will be by email.

    All papers must be submitted via the online system. If you would like to discuss your paper prior to submission, please refer to the contact details below.

    Submitting a Revision 
    Authors submitting revised manuscripts should follow the instructions above to submit through the SAGE track system. To create a revision, go to the ‘Manuscripts with Decisions’ option in your Author Dashboard and select ‘create a revision in the ‘Action’ column. Revised text should be highlighted in the text, and authors of all revised submissions should, when prompted, provide information explaining the changes in your manuscript as this will be provided to reviewers.

    All papers must be submitted via the online system. If you would like to discuss your paper prior to submission, please refer to the contact details below.

    Wendy Krank
    Managing Editor
    Cephalalgia Editorial Office
    Email: editorial.cephalalgia@gmail.com
     

    Back to top

     

    4. Publishing policies

    4.1 Plagiarism policy

    The Journal and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    4.2 Journal contributor’s publishing agreement   

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. For Cephalalgia copyright in the work will be assigned from the author to the society. It is a condition of acceptance that all manuscripts submitted must be original, not under consideration for publication elsewhere, and not previously published. For more information please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.

    4.3 SAGE Choice

    If you wish your article to be freely available online immediately upon publication (as some funding bodies now require), you can opt for it to be included in SAGE Choice subject to payment of a publication fee. The manuscript submission and peer reviewing procedure is unchanged. On acceptance of your article, you will be asked to let SAGE know directly if you are choosing SAGE Choice. For further information, please visit SAGE Choice.

    For any questions not covered on the Frequently Asked Questions page, please send an email to editorial.cephalalgia@gmail.com.

    Back to top

     

    5. Declaration of conflicting interests                  

    Within your Journal Contributor’s Publishing Agreement you will be required to make a certification with respect to a declaration of conflicting interests. It is the policy ofCephalalgia to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please include any declaration at the end of your manuscript after any acknowledgements and prior to the references, under a heading ‘Conflict of Interest Statement’. If no declaration is made, the following will be printed under this heading in your article: ‘None Declared’. Alternatively, you may wish to state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    When making a declaration, the disclosure information must be specific and include any financial relationship that all authors of the article have with any sponsoring organization and the for-profit interests that the organisation represents, and with any for-profit product discussed or implied in the text of the article.

    Any commercial or financial involvements that might represent an appearance of a conflict of interest need to be additionally disclosed in the covering letter accompanying your article to assist the Editor in evaluating whether sufficient disclosure has been made within the Conflict of Interest statement provided in the article.

    For more information please visit the SAGE Journal Author Gateway.

    Back to top

     

    6. Other conventions

    Papers based on clinical investigation must satisfy the Editorial Board that they conform to ethical standards as described in the Declaration of Helsinki. Acceptance of an investigational study by the appropriate ethical committee should be confirmed. Any form of registration that may identify a patient must be excluded from the content of the paper. When clinical photographs of patients are submitted, consent by the patient must be obtained prior to submission of the article. This is the responsibility of the author.

    ICMJE
    All materials should comply with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, prepared by the International Committee of Medical Journal Editors (ICMJE). All submissions should be accompanied by an ICMJE Uniform Disclosure Form for Potential Conflicts of Interest.

    Use standard abbreviations. Any non-standard abbreviations (to be avoided if possible) should be explained in the text the first time they are used. Avoid abbreviations in the title. Quantities and units should be expressed in accordance with the recommendations of the International System of Units (Système International d'Unités).

    Study Protocols
    If your article has a study protocol please upload it as a supporting file (see 9.4.8 for guidance on uploading supporting files). This is optional, but it will help us to evaluate the study.

    Back to top

     

    7. Acknowledgements                                                         

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    All contributors who do not meet the criteria for authorship should be listed in an `Acknowledgements’ section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.

    7.1 Funding Acknowledgement

    To comply with the guidance for Research Funders, Authors and Publishers issued by the Research Information Network (RIN), Cephalalgia additionally requires all Authors to acknowledge their funding in a consistent fashion under a separate heading. All research articles should have a funding acknowledgement in the form of a sentence as follows, with the funding agency written out in full, followed by the grant number in square brackets:

    This work was supported by the Medical Research Council [grant number xxx].

    Multiple grant numbers should be separated by comma and space. Where the research was supported by more than one agency, the different agencies should be separated by semi-colon, with “and” before the final funder. Thus:

    This work was supported by the Wellcome Trust [grant numbers xxxx, yyyy]; the Natural Environment Research Council [grant number zzzz]; and the Economic and Social Research Council [grant number aaaa].

    In some cases, research is not funded by a specific project grant, but rather from the block grant and other resources available to a university, college or other research institution. Where no specific funding has been provided for the research we ask that corresponding authors use the following sentence:

    This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

    IMPORTANT: If you have any concerns that the provision of this information may compromise your anonymity dependent on the peer review policy of this journal outlined above, you can withhold this information until final accepted manuscript.

    For more information on the guidance for Research Funders, Authors and Publishers, please click here.

    Back to top

     

    8. Permissions

    Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.

    Back to top

     

    9. Manuscript style

    9.1 File types

    Only electronic files conforming to the journal's guidelines will be accepted. Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. It is important that all figures/images and tables are uploaded as separate files and are not embedded into the main text file. Please also refer to additional guidelines on submitting artwork and supporting files below.

    9.2 Journal Style

    Cephalalgia conforms to the SAGE house style. Refer to Cephalalgia Manuscript Template.

    9.3 Reference Style

    Cephalalgia operates a SAGE Vancouver reference style. Click here to review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style. Also refer to Cephalalgia Manuscript Template.

    9.4. Manuscript Preparation

    The text should be double-spaced throughout and with a minimum of 3cm for left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point. SI units should be used throughout the text.

    Please see Section 2.1 for specific guidelines on research article preparation

    9.4.1 Title Page

    The first page of your manuscript should include the following information

    1. Title
    2. All author names and affiliations
    3. Corresponding author contact details
    4. Structured abstract (if applicable to manuscript type)
    5. Key words

    9.4.2 Keywords and Abstracts

    The title, keywords and abstract are key to ensuring that readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting SAGE’s Journal Author Gateway Guidelines on How to Help Readers Find Your Article Online.

    9.4.3 Structuring your abstract

    Given that Cephalalgia is a journal devoted to headache and facial pain, readers are familiar with these diseases. Generally please avoid platitutudes such as "migrane is a disabling disease and/or affects a high percentage of people" in the abstract and throughout the manuscript. The journal author guidelines require a structured abstract using 3 or 4 paragraphs without cite of references or abbreviations. Word count is not more than 250 words.

    Any papers received without a structured abstract will be returned to the corresponding author.

    9.4.4 Corresponding Author Contact details

    Full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors.

    9.4.5 Clinical relevance summaries

    In order to ensure that your research is of interest to as a wide an audience as possible it is important that you provide two to five bullet points summarizing your manuscript.  Use bullet points with headings such as Article Highlights or Key Findings if your research is basic science based. 
    If your article is clinically based please use bullet points with the heading Clinical Implications.  These bullet points will be reproduced in a summary box at the end of your article.  The summary box is created once the manuscript is accepted and moved off to the publisher.

    Please include the manuscript bullet points within the manuscript after the conclusion and prior to the reference list.  To complete the submission of your manuscript enter the same bullet points into the database.

    9.4.6 Guidelines for submitting artwork, figures and other graphics

    Artwork, figures and other graphics such as tables should be uploaded through SAGE’s Online Submission System alongside the main body of the text, as a separate file to ensure best quality in production. For further guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.

    9.4.7 Guidelines for submitting supplemental files

    This journal is able to host approved supplemental materials online, alongside the full-text of articles. Supplemental files will be subjected to peer-review alongside the article. For more information please refer to SAGE’s Guidelines for Authors on Supplemental Files.

    9.4.8 English Language Editing

    Non-English speaking authors who would like to refine their use of language in their manuscripts might consider using a professional editing service. Visit English Language Editing Services for further information.

    Back to top

     

    10. After acceptance

    10.1 Proofs

    We will email a PDF of the proofs to the corresponding author.

    10.2 E-Prints and Complimentary Copies

    SAGE provides authors with access to a PDF of their final article. For further information please visit Offprints and Reprints . We additionally provide the corresponding author with a complimentary copy of the print issue in which the article appears up to a maximum of 5 copies for onward supply by the corresponding author to co-authors.

    10.3 SAGE Production

    At SAGE we place an extremely strong emphasis on the highest production standards possible. We attach high importance to our quality service levels in copy-editing, typesetting, printing, and online publication (http://online.sagepub.com/). We also seek to uphold excellent author relations throughout the publication process.

    We value your feedback to ensure we continue to improve our author service levels. On publication all corresponding authors will receive a brief survey questionnaire on your experience of publishing in Cephalalgia with SAGE.

    10.4 OnlineFirst Publication

    Cephalalgia benefits from OnlineFirst, a feature offered through SAGE’s electronic journal platform, SAGE Journals. It allows final revision articles (completed articles in queue for assignment to an upcoming issue) to be hosted online prior to their inclusion in a final print and online journal issue which significantly reduces the lead time between submission and publication. For more information please visit our OnlineFirst Fact Sheet

    Back to top

     

    11. Further information

    Any correspondence, queries or additional requests for information should be sent to the Editorial Office as follows:

    Wendy Krank
    Managing Editor
    Cephalalgia Editorial Office
    Email: editorial.cephalalgia@gmail.com

    Back to top

    Please select a format:

    Individual Subscription, Combined (Print & E-access)


    Institutional Subscription, E-access


    Institutional Subscription, Print Only


    Institutional Subscription, Combined (Print & E-access)


    Institutional Subscription & Backfile Lease, E-access Plus Backfile (All Online Content)


    Institutional Subscription & Backfile Lease, Combined Plus Backfile (Current Volume Print & All Online Content)


    Institutional Backfile Purchase, E-access (Content through 1998)


    Individual, Single Print Issue


    Institutional, Single Print Issue